Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2022
2021
2020
Profitability Metrics
Gross Margin
100.00%
Operating Margin
76.47%
Net Margin
71.78%
Efficiency Metrics
Revenue per Expense Ratio
4.25
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
0.4800000000
Balance Sheet Analysis
Current Ratio
1.21
Cash Ratio
0.00
Working Capital
$2.47M
Debt to Equity
0.48
Debt to Assets
31.86%
Equity Ratio
66.90%
Cash Flow Analysis
Operating Cash Flow Ratio
60.76%
Free Cash Flow Ratio
60.76%
CapEx to Revenue
0.00%
Dividends Paid
$24.75M
Stock Buybacks
$2.45M
Total Shareholder Returns
$27.20M
Cash Position Change
-100.00%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
1,657.23%
Net Income
351.71%
EPS
300.00%
Operating Income
18.22%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
230.00%
Operating Cash Flow
-49.08%
Free Cash Flow
-49.08%
Balance Sheet Health
Assets
26.96%
Debt
3,247.28%
Book Value per Share
-1.29%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-4.24%
Shares Outstanding
26.16%
Long Term Trends
3Y Revenue/Share
-62.33%
5Y Revenue/Share
-38.34%
3Y Dividend/Share
-15.61%
5Y Dividend/Share
-36.59%